Erythromycin Oxime is a key intermediate for synthesizing various macrolide antibiotics, mainly used in the production of broad-spectrum antibacterial drugs such as azithromycin, roxithromycin, and clarithromycin. These antibiotics are widely used in clinical practice for the treatment of respiratory tract infections (such as pneumonia and bronchitis), skin and soft tissue infections, urogenital system infections, and diseases caused by special pathogens such as mycoplasma and chlamydia. Their derivatives are characterized by a broad antibacterial spectrum and strong tissue permeability, making them particularly suitable for patients allergic to penicillin. They are one of the important choices in anti-infective therapy.

Key Intermediate—As an important precursor for synthesizing a new generation of macrolide antibiotics (such as azithromycin), it has high chemical conversion value.

Broad-spectrum Antibacterial Activity—Retains the antibacterial activity of erythromycin and is effective against common pathogens causing respiratory and soft tissue infections.

Structural Stability—Oxime group modification enhances molecular stability, reduces degradation, and prolongs the storage period of preparations.

Structural Optimizability—Further chemical modification can be used to develop derivatives with stronger antibacterial activity and lower side effects.

Strict Quality Control—Complies with international pharmacopoeia standards to ensure low impurities, high purity, and medication safety.

Wide Formulation Adaptability—Suitable for the production of various formulations such as tablets, capsules, and injections.